Clinical trials
Neuroendocrine Tumors clinical trials
Below are recruiting neuroendocrine tumors clinical trials, each written for real people, not researchers. We’re tracking 161 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04665739RecruitingPhase 2
Lutetium Lu-177 for lung carcinoid tumors with somatostatin receptors
This trial tests lutetium Lu 177 dotatate, a targeted radiation treatment, for advanced lung neuroendocrine (carcinoid) tumors that have a specific marker called somatostatin receptors. It may help shrink tumors by delivering radiation directly to cancer cells that “light up” on a special scan.
Birmingham, AlabamaAges 18 years+ - NCT04074135RecruitingPhase 2
Study of pancreatic tumors in people with VHL
This trial studies the natural course and management of pancreatic neuroendocrine tumors in people with von Hippel–Lindau (VHL) disease. It may help doctors better predict how these pancreatic findings change over time and how to manage them.
Bethesda, MarylandAges 12 years+ - NCT04086485RecruitingPhase 1/Phase 2
Lu-177 dotatate plus olaparib for inoperable neuroendocrine tumors
This study tests whether combining Lu-177 dotatate (a targeted radiation treatment) with olaparib (a targeted pill) can shrink or slow growth of inoperable gastroenteropancreatic neuroendocrine tumors. It’s designed for tumors that show the right “targets” on a special scan and that have started to progress despite standard care.
Bethesda, MarylandAges 18–100 - NCT04090034Recruiting
PRRT for advanced neuroendocrine tumors
This trial tests a treatment called PRRT, which delivers a radioactive medicine directly to tumor cells, for advanced neuroendocrine tumors. It may help those whose tumors are growing despite octreotide treatment, especially when scans show tumor uptake of specific tracers.
Dallas, TexasAges 18 years+ - NCT07759960Recruiting
Removing small rectal tumors with two endoscopic methods
This study compares two minimally invasive ways to remove small rectal neuroendocrine tumors (NETs), which are growths in the rectum that are usually not cancer. The goal is to find which method is safer and more effective with fewer side effects.
Guangzhou, GuangdongAges 18–75 - NCT07357623RecruitingPhase 2
Surufatinib with or without chemo for lung neuroendocrine tumors
This trial tests whether adding chemotherapy to the drug surufatinib works better than surufatinib alone for people with a rare type of lung cancer called pulmonary neuroendocrine tumor. If you have this diagnosis and haven't had prior systemic treatment, you may be eligible.
Hefei, AnhuiAges 18–75 - NCT07165886RecruitingPhase 2/Phase 3
Study of sirolimus and octreotide for advanced neuroendocrine tumors
This trial tests a combination of two drugs, sirolimus and octreotide, for people with advanced neuroendocrine tumors in the digestive system that cannot be removed by surgery and are not making excess hormones. The goal is to see if this combination can help control the tumors.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05918302RecruitingPhase 3
Compare radiotherapy versus everolimus for lung and thymus tumors
This study compares two treatment options for somatostatin receptor–positive neuroendocrine tumors from the lung or thymus: radiotherapy versus everolimus. It aims to see which treatment works better and how safe each option is for people whose disease has progressed within the last year.
Edegem, EdegemAges 18 years+ - NCT02270567Enrolling by invitation
Registry study for neuroendocrine tumors in patients worldwide
This study keeps a worldwide record of people with neuroendocrine tumors to learn about care patterns and outcomes. It may help your doctors and future patients by improving how these tumors are monitored and treated.
Branford, ConnecticutAges 18 years+ - NCT06015802Recruiting
Predicting pituitary tumor behavior with markers and scans
This study looks at whether blood and tissue markers, along with imaging features, can predict how aggressive a pituitary neuroendocrine tumor is and how it may affect long-term health. It aims to improve treatment decisions by better understanding these tumors.
Guangzhou, GuangdongAges 18–70 - NCT04282083Recruiting
Registry for adults with confirmed digestive neuroendocrine tumors
This is a registry study that collects medical information from adults with neuroendocrine tumors (NETs) that start in the digestive organs. It helps researchers understand these cancers better and may support future studies.
Rozzano, MilanAges 18 years+ - NCT06663072RecruitingPhase 1
Testing fulvestrant plus lutetium therapy for advanced pancreatic neuroendocrine tumors
This trial tests a new combination of two drugs: lutetium-177 DOTATATE (a type of radiation therapy that targets tumor cells) and fulvestrant (a hormonal therapy). It is for people with advanced pancreatic neuroendocrine tumors that have grown despite previous treatments.
Chicago, IllinoisAges 18 years+ - NCT06505824RecruitingPhase 1
Study of BL-M14D1 for advanced lung cancer and other solid tumors
This trial tests a new drug, BL-M14D1, for people with advanced small cell lung cancer, neuroendocrine tumors, or other solid tumors that have no standard treatment. The goal is to see if the drug is safe and possibly effective.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05884255RecruitingPhase 3
Lutetium brain-sparing therapy for advanced gut and pancreas tumors
This Phase 3 trial tests lutetium (Lu-177) oxodotreotide, a targeted treatment, for people with advanced gut and pancreas neuroendocrine tumors that are low or medium grade (G1 or G2). The study will see whether it helps control the cancer and symptoms in the right patients.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT04339036RecruitingPhase 2
CapTem plus Y-90 for liver-spread neuroendocrine tumors
This Phase 2 study tests whether combining capecitabine/temozolomide (“CapTem”) with Y-90 treatment can shrink neuroendocrine tumor (NET) spread in the liver. It may help people whose tumor is mostly in the liver and cannot be fully removed with surgery.
La Jolla, CaliforniaAges 18 years+ - NCT02146170Recruiting
Blood and tissue collection study for several lung and chest cancers
This study collects tissue (and follows patients over time) to better understand the natural course of several types of chest cancers. It may help researchers learn which tests and treatments work best in different cancer types.
Bethesda, MarylandAges 18 years+ - NCT06679816RecruitingPhase 4
Hydrocortisone for hormone replacement in large pituitary tumor surgery
This trial tests hydrocortisone as hormone replacement therapy after surgery for large pituitary tumors. It aims to help patients maintain healthy cortisol levels during recovery.
Beijing, Beijing MunicipalityAges 18–70 - NCT06624865Recruiting
Gut bacteria and small-intestine neuroendocrine tumor study
This study looks at how bacteria in your gut may affect the growth of small-intestine neuroendocrine tumors. If you are having surgery to remove one of these tumors, the research team will collect samples and data to better understand the link between your gut bacteria and the tumor.
Lyon, FranceAges 18 years+ - NCT07114939RecruitingPhase 1
A new pet scan for pancreatic neuroendocrine tumors
This study is testing a special type of PET/CT scan using a tracer called FTT to see if it can better find and track pancreatic neuroendocrine tumors that have spread or cannot be removed by surgery. The goal is to improve imaging for people with this type of cancer.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06479811RecruitingPhase 1
Radioactive drug for advanced neuroendocrine and other cancers
This early-stage trial tests a new radioactive drug (called [212Pb]VMT-Alpha-NET) that targets a marker on certain cancer cells. It may help shrink or slow the growth of tumors that have spread or can't be removed, and it's being studied for several cancer types, including neuroendocrine tumors, small cell lung cancer, kidney cancer, and some head and neck cancers.
Bethesda, MarylandAges 18–120 - NCT05263050RecruitingPhase 2
Trial tests a new cabozantinib schedule for kidney and neuroendocrine tumors
This Phase 2 study tests a different dosing schedule of cabozantinib (a cancer medicine) for metastatic kidney cancer and certain neuroendocrine tumors. It aims to see if the timing and schedule can work well for people with advanced disease.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07366658RecruitingPhase 1
Experimental therapy for neuroendocrine tumors that did not respond to treatment
This trial tests an experimental therapy (NEUK203-13) for people with neuroendocrine tumors, including small cell lung cancer, that have not responded to or stopped responding to standard treatments. It aims to see if the drug is safe and to look for early signs that it might shrink tumors, especially in people whose tumors have a specific marker called DLL3.
BeijingAges 18–75 - NCT06455358RecruitingPhase 1/Phase 2
A new PET scan to find neuroendocrine tumors
This trial tests a new type of PET scan using a radioactive tracer called 61Cu-NODAGA-LM3 to detect neuroendocrine tumors (NETs). The goal is to see if it works as well as or better than the standard scan. If you have a NET and need a scan for staging or treatment planning, you might be able to join.
Basel, Canton of Basel-CityAges 18 years+ - NCT06878664RecruitingPhase 3
Lu177-Dotatate vs standard care for slow-growing midgut neuroendocrine tumors
This trial tests whether a radioactive drug called Lu177-Dotatate (PRRT) works better than usual care for people with slow-growing, advanced midgut neuroendocrine tumors (NETs). It may help shrink or slow the growth of tumors when you also get somatostatin analog therapy.
Caen, CaenAges 18 years+
Hear when a new Neuroendocrine Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for neuroendocrine tumors?
- Yes. Clin2 currently lists 161 recruiting neuroendocrine tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a neuroendocrine tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a neuroendocrine tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.